Safety and Tolerability of Intravenous LFG316 in Wet Age-related Macular Degeneration (AMD).

Inclusion Criteria: \- Active choroidal neovascular AMD in at least one eye. Exclusion Criteria: * Retinal disease other than AMD that, in the investigator's opinion, would interfere with safety or study conduct. * Choroidal neovascularization due to a cause other than AMD. * In the study eye, media opacity that, in the investigator's opinion, would interfere with study conduct. * Any disease or concomitant (or recent) medication expected to cause systemic immunosuppression. * History of meningococcal meningitis in the past 10 years, or any history of recurrent meningitis. * History of hospitalization for pneumococcal pneumonia within the past 3 years. * History of serious systemic infection within the past 12 months. * Any of the following treatments to the study eye within 7 days prior to study drug dosing: ranibizumab (Lucentis), bevacizumab (Avastin), pegaptanib (Macugen), or other VEGF inhibitor. Other protocol-defined inclusion/exclusion criteria may apply